Company News: Drugmakers, Duke Energy, Chrysler, Adobe Systems, Dalian Wanda
This article is for subscribers only.
• Makers of brand-name drugs can be sued for a long-standing practice of paying competitors to postpone the release of cheaper generic treatments, the U.S. Supreme Court ruled in a 5-3 decision. According to the Federal Trade Commission, there were 40 pay-for-delay agreements last year, costing drug consumers an additional $3.5 billion. The industry’s trade group said the ruling would dent research.